Drug news
CHMP recommends Rienso (Takeda) for Iron Deficiency Anaemia
)The CHMP has recommended marketing authorisation for Rienso, 30 /ml, solution for injection from Takeda, being the intravenous treatment of Iron Deficiency Anaemia in adult atients with Chronic Kidney Disease. The active substance of Rienso is ferumoxytol, a colloidal iron-carbohydrate complex. Upon release from the complex, the iron either enters the intracellular storage iron pool (e.g., ferritin) or is transferred to plasma transferrin for transport to erythroid precursor cells for incorporation into haemoglobin. The benefits with Rienso are its ability to increase haemoglobin levels.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins